Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
2.

The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study.

Baretti M, Pulluri B, Tsai HL, Blackford AL, Wolfgang CL, Laheru D, Zheng L, Herman J, Le DT, Narang AK, de Jesus-Acosta A.

Pancreas. 2019 Feb 26. doi: 10.1097/MPA.0000000000001262. [Epub ahead of print]

PMID:
30817723
3.

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy.

Cheng Z, Rosati LM, Chen L, Mian OY, Cao Y, Villafania M, Nakatsugawa M, Moore JA, Robertson SP, Jackson J, Hacker-Prietz A, He J, Wolfgang CL, Weiss MJ, Herman JM, Narang AK, McNutt TR.

Adv Radiat Oncol. 2018 Jul 19;3(4):601-610. doi: 10.1016/j.adro.2018.07.002. eCollection 2018 Oct-Dec.

4.

Neoadjuvant Short-Course Radiation Therapy for Rectal Cancer: Trends and Controversies.

Narang AK, Meyer J.

Curr Oncol Rep. 2018 Jul 5;20(9):68. doi: 10.1007/s11912-018-0714-x. Review.

PMID:
29978358
5.

Stereotactic body radiation therapy for palliative management of pancreatic adenocarcinoma in elderly and medically inoperable patients.

Ryan JF, Rosati LM, Groot VP, Le DT, Zheng L, Laheru DA, Shin EJ, Jackson J, Moore J, Narang AK, Herman JM.

Oncotarget. 2018 Mar 27;9(23):16427-16436. doi: 10.18632/oncotarget.24713. eCollection 2018 Mar 27.

6.

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.

Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J.

Ann Surg. 2018 Jun 18. doi: 10.1097/SLA.0000000000002753. [Epub ahead of print]

PMID:
29596120
7.

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers.

Schunke KJ, Rosati LM, Zahurak M, Herman JM, Narang AK, Usach I, Klein AP, Yeo CJ, Korman LT, Hruban RH, Cameron JL, Laheru DA, Abrams RA.

Adv Radiat Oncol. 2017 Aug 3;3(1):42-51. doi: 10.1016/j.adro.2017.07.008. eCollection 2018 Jan-Mar.

8.

Effects of perineural invasion on biochemical recurrence and prostate cancer-specific survival in patients treated with definitive external beam radiotherapy.

Peng LC, Narang AK, Gergis C, Radwan NA, Han P, Marciscano AE, Robertson SP, He P, Trieu J, Ram AN, McNutt TR, Griffith E, DeWeese TA, Honig S, Singh H, Greco SC, Tran PT, Deville C, DeWeese TL, Song DY.

Urol Oncol. 2018 Jun;36(6):309.e7-309.e14. doi: 10.1016/j.urolonc.2018.02.008. Epub 2018 Mar 16.

PMID:
29551548
9.

Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.

Hayman J, Phillips R, Chen D, Perin J, Narang AK, Trieu J, Radwan N, Greco S, Deville C Jr, McNutt T, Song DY, DeWeese TL, Tran PT.

Prostate. 2018 Jun;78(8):623-630. doi: 10.1002/pros.23507. Epub 2018 Mar 9.

PMID:
29520847
10.

Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.

Herman JM, Jabbour SK, Lin SH, Deek MP, Hsu CC, Fishman EK, Kim S, Cameron JL, Chekmareva M, Laheru DA, Narang AK, Pawlik TM, Hruban RH, Wolfgang CL, Iacobuzio-Donahue CA.

Pancreas. 2018 Feb;47(2):208-212. doi: 10.1097/MPA.0000000000000985.

11.

A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review.

Rosati LM, Kummerlowe MN, Poling J, Hacker-Prietz A, Narang AK, Shin EJ, Le DT, Fishman EK, Hruban RH, Yang SC, Weiss MJ, Herman JM.

Oncotarget. 2017 Jun 12;8(59):100942-100950. doi: 10.18632/oncotarget.18458. eCollection 2017 Nov 21.

12.

Multiplex Proximity Ligation Assay to Identify Potential Prognostic Biomarkers for Improved Survival in Locally Advanced Pancreatic Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Rao AD, Liu Y, von Eyben R, Hsu CC, Hu C, Rosati LM, Parekh A, Ng K, Hacker-Prietz A, Zheng L, Pawlik TM, Laheru DA, Jaffee EM, Weiss MJ, Le DT, Hruban RH, De Jesus-Acosta A, Wolfgang CL, Narang AK, Chang DT, Koong AC, Herman JM.

Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):486-489. doi: 10.1016/j.ijrobp.2017.10.001. Epub 2017 Oct 12.

PMID:
29157747
13.

Adjuvant Chemoradiotherapy is Associated with Improved Survival for Patients with Resected Gallbladder Carcinoma: A Systematic Review and Meta-analysis.

Kim BH, Kwon J, Chie EK, Kim K, Kim YH, Seo DW, Narang AK, Herman JM.

Ann Surg Oncol. 2018 Jan;25(1):255-264. doi: 10.1245/s10434-017-6139-1. Epub 2017 Oct 27.

PMID:
29079926
14.

Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective.

Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, Weiss MJ, Wolfgang CL, Herman JM.

Ann Surg Oncol. 2018 Jan;25(1):280-289. doi: 10.1245/s10434-017-6134-6. Epub 2017 Oct 23.

PMID:
29063299
15.

Socioeconomic factors affect the selection of proton radiation therapy for children.

Shen CJ, Hu C, Ladra MM, Narang AK, Pollack CE, Terezakis SA.

Cancer. 2017 Oct 15;123(20):4048-4056. doi: 10.1002/cncr.30849. Epub 2017 Jun 27.

16.

Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.

Narang AK, Nicholas LH.

JAMA Oncol. 2017 Jun 1;3(6):757-765. doi: 10.1001/jamaoncol.2016.4865.

17.

Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy.

Choflet A, Narang AK, Herald Hoofring L, Bonerigo S, Mian OY, Katulis L, Cheng Z, Appling S.

Clin J Oncol Nurs. 2016 Aug 1;20(4):397-402. doi: 10.1188/16.CJON.397-402.

PMID:
27441512
18.

Progressive Low-Grade Glioma: Assessment of Prognostic Importance of Histologic Reassessment and MRI Findings.

Narang AK, Chaichana KL, Weingart JD, Redmond KJ, Lim M, Olivi A, Quinones-Hinojosa A, Kleinberg LR.

World Neurosurg. 2017 Mar;99:751-757. doi: 10.1016/j.wneu.2016.04.030. Epub 2016 Apr 19.

PMID:
27108796
19.

Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation.

Narang AK, Gergis C, Robertson SP, He P, Ram AN, McNutt TR, Griffith E, DeWeese TA, Honig S, Singh H, Song DY, Tran PT, DeWeese TL.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):254-62. doi: 10.1016/j.ijrobp.2015.10.056. Epub 2015 Oct 31.

20.

Prostate cancer: Case volume and improved outcomes across cancer care.

Narang AK, Tran PT.

Nat Rev Urol. 2016 Apr;13(4):186-7. doi: 10.1038/nrurol.2016.15. Epub 2016 Feb 2. No abstract available.

21.

Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience.

Wang J, Narang AK, Sugar EA, Luber B, Rosati LM, Hsu CC, Fuller CD, Pawlik TM, Miller RC, Czito BG, Tuli R, Crane CH, Ben-Josef E, Thomas CR Jr, Herman JM.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1100-6. doi: 10.1245/s10434-015-4685-y. Epub 2015 Jul 30.

PMID:
26224402
22.

Trends in Advance Care Planning in Patients With Cancer: Results From a National Longitudinal Survey.

Narang AK, Wright AA, Nicholas LH.

JAMA Oncol. 2015 Aug;1(5):601-8. doi: 10.1001/jamaoncol.2015.1976.

23.

Contemporary radiation therapy in combined modality therapy for Hodgkin lymphoma.

Narang AK, Terezakis SA.

J Natl Compr Canc Netw. 2015 May;13(5):597-605. Review.

PMID:
25964643
24.

The promise of modern radiotherapy in resected pancreatic adenocarcinoma: a response to Bekaii-Saab et al.

Narang AK, Herman JM.

Ann Surg Oncol. 2014 Apr;21(4):1064-6. doi: 10.1245/s10434-013-3344-4. Epub 2014 Feb 13. No abstract available.

PMID:
24522986
25.

Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

Walker AJ, Alcorn SR, Narang AK, Nugent KM, Wild AT, Herman JM, Tran PT.

Curr Probl Cancer. 2013 Sep-Oct;37(5):301-12. doi: 10.1016/j.currproblcancer.2013.10.008. Epub 2013 Oct 5. Review. No abstract available.

26.

The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, Tran PT, Grossman SA, Herman JM.

Am J Clin Oncol. 2015 Jun;38(3):259-65. doi: 10.1097/COC.0b013e3182940ff9.

27.

Accuracy of marketing claims by providers of stereotactic radiation therapy.

Narang AK, Lam E, Makary MA, Deweese TL, Pawlik TM, Pronovost PJ, Herman JM.

J Oncol Pract. 2013 Jan;9(1):57-62. doi: 10.1200/JOP.2012.000693.

28.

The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer.

Herman JM, Narang AK, Griffith KA, Zalupski MM, Reese JB, Gearhart SL, Azad NS, Chan J, Olsen L, Efron JE, Lawrence TS, Ben-Josef E.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e15-9. doi: 10.1016/j.ijrobp.2012.09.006. Epub 2012 Oct 9.

29.

Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer.

Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM, Swartz MJ, Winter JM, Robinson R, Edil BH, Narang AK, Choti MA, Hruban RH, Cameron JL, Schulick RD, Herman JM.

J Gastrointest Surg. 2012 Apr;16(4):753-61. doi: 10.1007/s11605-011-1811-4. Epub 2012 Feb 7.

30.

Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiation.

Rudra S, Narang AK, Pawlik TM, Wang H, Jaffee EM, Zheng L, Le DT, Cosgrove D, Hruban RH, Fishman EK, Tuli R, Laheru DA, Wolfgang CL, Diaz LA Jr, Herman JM.

Pract Radiat Oncol. 2012;2(2):77-85.

31.

Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.

Narang AK, Miller RC, Hsu CC, Bhatia S, Pawlik TM, Laheru D, Hruban RH, Zhou J, Winter JM, Haddock MG, Donohue JH, Schulick RD, Wolfgang CL, Cameron JL, Herman JM.

Radiat Oncol. 2011 Sep 28;6:126. doi: 10.1186/1748-717X-6-126.

32.

Resectable pancreatic small cell carcinoma.

Winter JM, Narang AK, Mansfield AS, Herman JM, Cameron JL, Laheru D, Eckhauser FE, Olson MT, Hruban RH, Miller RC, Andersen DK.

Rare Tumors. 2011 Mar 30;3(1):e5. doi: 10.4081/rt.2011.e5.

33.

Inheritance of a novel COL8A2 mutation defines a distinct early-onset subtype of fuchs corneal dystrophy.

Gottsch JD, Sundin OH, Liu SH, Jun AS, Broman KW, Stark WJ, Vito EC, Narang AK, Thompson JM, Magovern M.

Invest Ophthalmol Vis Sci. 2005 Jun;46(6):1934-9.

PMID:
15914606

Supplemental Content

Loading ...
Support Center